

PROVIDER BULLETIN

No. 10-07

March 29, 2010

TO: All physicians, pharmacists, and pharmacies participating in the Nebraska Medicaid Program

FROM: Vivianne M. Chaumont, Director 
Division of Medicaid and Long-Term Care

RE: Preferred Drug List (PDL)

PDL EXPANSION:

New therapeutic classes being added to the Preferred Drug List are listed below. To see a complete listing of the Preferred Drug List, go to <https://nebraska.fhsc.com/> under the Preferred Drug List tab.

IMPLEMENTATION 3/31/2010	IMPLEMENTATION 4/28/2010
Acne Agents, Topical	Angiotensin Modulators
Analgesics, Opiate, Long-Acting	<ul style="list-style-type: none">• Angiotensin-Converting Enzyme Inhibitors
Analgesics, Opiate, Short-Acting	<ul style="list-style-type: none">• Direct Renin Inhibitors
Antibiotics, Gastrointestinal	<ul style="list-style-type: none">• Angiotensin II Receptor Blockers
Antimigraine Drugs, Triptans	<ul style="list-style-type: none">• Combination with calcium channel blocker products
Benign Prostatic Hyperplasia (BPH) Treatments	Anticoagulants – Injectable
Colony Stimulating Factors	Antihistamines, Minimally Sedating
Erythropoiesis Stimulating Proteins	Beta-Blockers
Growth Hormone	Bladder Relaxant Preparations
Hepatitis C Treatment	Calcium Channel Blockers
Impetigo Drugs, Topical	Hypoglycemics, Meglitinides
Multiple Sclerosis Drugs	Hypoglycemics, Thiazolidinediones
Otic Antibiotics	Lipotropics, Other
Proton Pump Inhibitors	Lipotropics, Statins
Sedative Hypnotics	Pulmonary Arterial Hypertension
Skeletal Muscle Relaxants	Phosphate Binders
Ulcerative Colitis	

This concludes the implementation phases of the Preferred Drug List. New therapeutic classes and new medications will be added to the List as necessary. Annual re-reviews will be completed for each class on an ongoing basis.

Thank you to all providers for cooperating and helping to make this program a success.

GENERIC MEDICATIONS:

In some cases, brand name products will have a lower net cost to the state than the generic equivalent. When this happens, the brand name product may be preferred over the generic formulation. When new generics become available, the generic form of a preferred branded product might not be added to the PDL right away. Prices will be monitored. When the net cost to the state becomes comparable or less expensive than the brand, the generic will then be added to the Preferred Drug List.

For further information about the Preferred Drug List and the Pharmaceutical and Therapeutics Committee, please look on the Pharmacy First Health website under the Preferred Drug List tab: <https://nebraska.fhsc.com/> or contact Jenny Minchow R.P., Pharm.D. at (402) 471-9109 , or email at dhhs.MedicaidPharmacyunit@nebraska.gov .